MIST
Milestone Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.20
−0.72%Sep 3, 2026, 05:14 UTC
China's National Medical Products Administration approved the launch of Milestone Pharmaceuticals Inc.'s etripamil nasal spray (brand name: Xingbituo) for treating acute episodes of paroxysmal supraventricular tachycardia in adults.
Aug 21, 2026, 12:00 UTC
Milestone Pharmaceuticals initiated the pivotal Phase 3 ReVeRA-301 trial of its etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).
Source:Aug 12, 2026, 00:00 UTC
Milestone Pharmaceuticals Inc. reported Q2 2026 financial results with product revenue of $0.6 million, a net loss of $28.6 million, and diluted EPS of -$0.21, as of June 30, 2026.
Jul 3, 2026, 01:30 UTC
Milestone Pharmaceuticals granted equity awards to six new employees as a material inducement to their hiring.
Source:Jun 15, 2026, 00:00 UTC
Milestone Pharmaceuticals Inc. elected Joseph Oliveto, Stuart M. Duty, Seth H.Z. Fischer, Lisa M. Giles, and Joseph C. Papa as directors effective June 10, 2026.